SCHEMBL6068324

SCHEMBL6068324

Nc1ccc(Sc2ccc(F)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.74
CYP3A4 P08684 1/20 0.74
TSHR P16473 1/20 0.74
MAPT P10636 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
PDE7A Q13946 3/20 0.49
ALDH1A1 P00352 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 1/20 0.46
GFER P55789 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ANXA2 P07355 1/20 0.42
S100A10 P60903 1/20 0.42
SERPINH1 P50454 1/20 0.42
MAOB P27338 2/20 0.42
POLB P06746 1/20 0.42
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL576260 0.86 MEN1 (0.48) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL9647870 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL9485438 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL1098379 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL10813732 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL9485453 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
4,4'-Thiodianiline SCHEMBL49068 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL9649030 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL9649049 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1
SCHEMBL9647766 0.86 CYP3A4 (1.00) MAPK1CYP3A4TSHRMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852135-A N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 CN disclosed
EP-2739626-B1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INT BV (NL) 2016-05-04 EP disclosed
EP-2739626-B1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INT BV (NL) 2016-05-04 EP disclosed
US-9096599-B2 Spiroindoline compounds INTERVET INC. (US) 2015-08-04 US disclosed
US-9096599-B2 Spiroindoline compounds INTERVET INC. (US) 2015-08-04 US disclosed
US-9096599-B2 Spiroindoline compounds INTERVET INC. (US) 2015-08-04 US disclosed
US-20140163056-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INC. 2014-06-12 US disclosed
US-20140163056-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INC. 2014-06-12 US disclosed
US-20140163056-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INC. 2014-06-12 US disclosed
EP-2739626-A1 NOVEL SPIROINDOLINE COMPOUNDS Intervet International B.V. (NL) 2014-06-11 EP disclosed
WO-2013017678-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INTERNATIONAL B.V. (NL) 2013-02-07 WO disclosed
WO-2013017678-A1 NOVEL SPIROINDOLINE COMPOUNDS INTERVET INTERNATIONAL B.V. (NL) 2013-02-07 WO disclosed
US-7091227-B2 Benzothiazole derivatives ABBOTT GMBH & CO. KG (DE) 2006-08-15 US disclosed
US-20030153568-A1 Benzothiazole derivatives BASF AKTIENGESELLSCHAFT LUDWIGSHAFEN, GERMANY 2003-08-14 US disclosed
EP-1254123-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS Abbott GmbH & Co. KG (DE) 2002-11-06 EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 WO disclosed
EP-0102476-B1 METHOD OF MODULATING THE IMMUNE RESPONSE SYSTEM IN MAMMALS AMERICAN CYANAMID COMPANY (US) 1986-11-05 EP disclosed
US-4532349-A 2-Amino-4'(phenylsulfonyl) acetanilides AMERICAN CYANAMID COMPANY (US) 1985-07-30 US disclosed
EP-0102476-A1 Method of modulating the immune response system in mammals AMERICAN CYANAMID COMPANY (US) 1984-03-14 EP disclosed
US-4072696-A 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity SYNTEX (U.S.A.) INC. (US) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153568-A1 Benzothiazole derivatives TK1, FLT1, CDK1 MAPK1 149/4885CYP3A4 1122/4885TSHR 2355/4885
US-20140163056-A1 NOVEL SPIROINDOLINE COMPOUNDS PKD2, PKD1, REN MAPK1 2303/4885CYP3A4 295/4885TSHR 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.